BioprintingMoney & FundingStocks

CELLINK moves to NASDAQ Main Market Mid-Cap Index

Less than five years since it was founded by a young team looking to produce and sell bioinks to the then very young bioprinting market, CELLINK is moving up to the NASDAQ Stockholm Main Market Mid-Cap

In this short time span, the firm that originated in Gotheborg, Sweden expanded operations to the US (Boston) and now to 6 countries, with a global team of over 200 individuals and with nearly 1,000 bioprinting labs as customers around the globe.

The approval is conditional upon the fulfillment of customary conditions, among others that a prospectus is approved and registered by the Swedish Financial Supervisory Authority (“SFSA”). The trading of the Company’s shares on Nasdaq Stockholm Main Market is expected to commence on Monday, April 20, 2020, and the last day of trading on Nasdaq First North Growth Market is expected to be Friday 17 April.

CELLINK’s shares will continue to be traded under the same ticker (CLNK) and ISIN code (SE0013647385). No new shares will be issued in connection with the listing. Shareholders of CELLINK do not need to take any action in connection with the listing on Nasdaq Stockholm Main Market.

CELLINK moves to NASDAQ

The listing on Nasdaq Stockholm is expected to attract a broader group of investors and give CELLINK greater access to the Swedish and international capital markets. The listing on Nasdaq Stockholm Main Market is also expected to improve the ability for CELLINK to acquire new companies, raise capital and continue to pursue the organic growth strategy.

CELLINK’s Board of Directors and management believes that the listing on Nasdaq Stockholm is an important step in the development of the Company. The listing on Nasdaq Stockholm Main Market is expected to further increase the awareness about CELLINK from existing and new potential shareholders, customers and suppliers. For these reasons, the board of directors of CELLINK has made the assessment that a listing on Nasdaq Stockholm will support the Company’s next steps towards its long-term targets.

In the fiscal year 2018-2019 the company recorded total revenues for 105,000 SEK (€9.5 million), an increase of 131% compared to the previous fiscal year. The company’s position on the world market has been strengthened as a result of continued investment in product development and two strategic acquisitions: the acquisition of the German single-cell printing company cytena GmbH was completed in August and the acquisition of the German dispensing company Dispendix GmbH was finalized in December. Direct sales during the year made up 50% of the company’s revenue and have increased from 40% to over 60% compared to the previous year. During the past fiscal year, CELLINK and its subsidiaries have successfully progressed within the pharmaceutical industry and sold their technology platform to the majority of the world’s 25 largest pharmaceutical companies.

 

Tags

Davide Sher

Since 2002, I have built up extensive experience as a technology journalist, market analyst and consultant for the additive manufacturing industry. Born in Milan, Italy, I spent 12 years in the United States, where I received my Bachelor of Arts undergraduate degree. As a journalist covering the tech industry - especially the videogame industry - for over 10 years, I began covering the AM industry specifically in 2013, as blogger. In 2016 I co-founded London-based 3D Printing Business Media Ltd. (now 3dpbm) which operates in marketing, editorial, and market analysis & consultancy services for the additive manufacturing industry. 3dpbm publishes 3D Printing Business Directory, the largest global directory of companies related to 3DP, and leading news and insights websites 3D Printing Media Network and Replicatore. I am also a Senior Analyst for leading US-based firm SmarTech Analysis focusing on the additive manufacturing industry and relative vertical markets.

Related Articles

Back to top button

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • PHPSESSID
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services
Close
Close

STAY AHEAD

OF THE CURVE

Join industry leaders and receive the latest insights on what really matters in AM!

This information will never be shared with 3rd parties

I’ve read and accept the privacy policy.*

WELCOME ON BOARD!